The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee

Clinical Therapeutics

Volumn 18, Issue 1, 1996, Pages 114-124

  Makarowski, William ^a   Weaver, Arthur ^b   Rubin, Bernard ^c   Caldwell, Jacques ^d   McMahon, F Gilbert ^e   Noveck, Robert J ^e   Lee, David ^f   Offenberg, Howard ^g   Sack, Marshall ^h   Sikes, David ⁱ   Trapp, Robert ^j   Rush, Susan ^k   Kuss, Michael ^k   Ganju, Jitendra ^k   Bocanegra, Tomás S ^k   Ratliff, James M ^k  

^a Rheumatology Associates   (United States)

^b Arthritis Center of Nebraska   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d Gainesville Clinical Research Center   (United States)

^e General Clinical Research Center New Orleans   (United States)

^f Walker Clinical Evaluations Inc   (United States)

^g Halifax Research Center   (United States)

^h Center for Clinical Research   (United States)

ⁱ Florida Medical Clinic   (United States)

^j Arthritis Center   (United States)

^k PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NABUMETONE; OXAPROZIN; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGY; HUMAN; JOINT MOBILITY; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS;

EID: 9444241472     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80184-6     Document Type: Article

References (19)

1. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs - differences and similarities. NEJM. 1991;324:1716-1725.
2. Simon LS. Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 1995;7:159-166.
3. Paulus HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 3rd ed, Vol. 1. Philadelphia: WB Saunders Company; 1989: 765-791.
4. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rheum. 1995;38:5-18.
5. Waxman J. The efficacy and safety of oxaprozin versus piroxicam: Pooled results of double-blind trials in osteoarthritis. Drug Ther. March 1993;Suppl:13-16.
6. Appelrouth DJ, Chodock AL, Miller JL, et al. A comparison of single daily doses of oxaprozin with multiple daily doses of ibuprofen for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1986;15 (Suppl 2):54-58.
7. Barber JV, Collins RL, Kitridou RC, et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of rheumatoid arthritis: A comparison with aspirin. Semin Arthritis Rheum. 1986;15 (Suppl 2):47-53.
8. Ginsberg F, Famaey JP. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis. Curr Med Res Opin. 1985;8:689-695.
9. Kolodny AL, Klipper AR, Harris BK, et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of osteoarthritis: A comparison with aspirin. Semin Arthritis Rheum. 1986;15(Suppl 2):72-79.
10. Pisko EJ, Bockow BI, Box P, et al. Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. Am J Med. 1987;83(Suppl 4B):86-91.
11. Nunn B, Chamberlain PD. Effect of nabumetone (BRL14777), a new anti-inflammatory drug, on human platelet reactivity ex-vivo: Comparison with naproxen. J Pharm Pharmacol. 1982;34:576-579.
12. Appelrouth DJ, Baim S, Chang RW, et al. Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. Am J Med. 1987;83(Suppl 4B):78-81.
13. Powell WR, Miller JL, Sheldon WB. Once-daily oxaprozin and piroxicam compared in osteoarthritis. Semin Arthritis Rheum. 1986;15(Suppl 2):80-85.
14. Physicians' Desk Reference.® 50th ed. Montvale, NJ: Medical Economics Data Production Company; 1996:2314-2316, 2395-2397.
15. Scott-Levin Physician Drug and Diagnosis Audit. 1995.
16. Weaver A, Rubin B, Caldwell J, et al. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther. 1995;17:735-745.
17. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
19. Carr AJ, Thompson PW. Towards a measure of patient-perceived handicap in rheumatic arthritis. Br J Rheumatol. 1994; 33:378-382.